title: Hyperammonemia-induced toxicity for the developing central nervous system.
abstract: In pediatric patients, hyperammonemia can be caused by various acquired or inherited disorders such as urea cycle deficiencies or organic acidemias. The brain is much more susceptible to the deleterious effects of ammonium during development than in adulthood. Hyperammonemia can provoke irreversible damages to the developing central nervous system that lead to cortical atrophy, ventricular enlargement and demyelination, responsible for cognitive impairment, seizures and cerebral palsy. Until recently, the mechanisms leading to these irreversible cerebral damages were poorly understood. Using experimental models allowing the analysis of the neurotoxic effects of ammonium on the developing brain, these last years have seen the emergence of new clues showing that ammonium exposure alters several amino acid pathways and neurotransmitter systems, as well as cerebral energy metabolism, nitric oxide synthesis, oxidative stress, mitochondrial permeability transition and signal transduction pathways. Those alterations may explain neuronal loss and impairment of axonal and dendritic growth observed in the different models of congenital hyperammonemia. Some neuroprotective strategies such as the potential use of NMDA receptor antagonists, nitric oxide inhibitors, creatine and acetyl-l-carnitine have been suggested to counteract these toxic effects. Unraveling the molecular mechanisms involved in the chain of events leading to neuronal dysfunction under hyperammonemia may be useful to develop new potential strategies for neuroprotection.
authors: Clinical Chemistry Laboratory, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CI 02/33, Avenue Pierre-Decker 2, CH-1011 Lausanne, Switzerland.
authors: Laurène
authors: L
authors: Cagnon
authors: Olivier
authors: O
authors: Braissant
mesh_terms: D000641:Ammonia / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000254:growth & development* / Q000378:metabolism / Q000503:physiopathology*; D020739:Brain Diseases, Metabolic, Inborn / Q000378:metabolism / Q000503:physiopathology*; D002547:Cerebral Palsy / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D002648:Child; D004734:Energy Metabolism / Q000502:physiology; D006801:Humans; D022124:Hyperammonemia / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology*; D008607:Intellectual Disability / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D009410:Nerve Degeneration / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D015518:Rett Syndrome / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000641:Ammonia